George Dickson

Royal Holloway University of London — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

55h-index11.2kcitations300works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Muscle Physiology and Disorders(173), Virus-based gene therapy research(96), CRISPR and Genetic Engineering(43), RNA Interference and Gene Delivery(42), Neurogenetic and Muscular Disorders Research(38)

Publications299 total

Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation
Methods in molecular biology·2025
Duchenne muscular dystrophy
Garland Science eBooks·2024· 4 cited
Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression
Biomedicines·2022· 17 citedOpen Access
Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I
Molecular Therapy — Nucleic Acids·2022· 15 citedOpen Access
Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMDmdx rat model
Gene Therapy·2022· 17 cited
Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy
Human Gene Therapy·2022· 13 cited
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
Nucleic Acid Therapeutics·2021· 115 citedOpen Access
A new strategy to increase RNA editing at the Q/R site of GluA2 AMPA receptor subunits by targeting alternative splicing patterns of ADAR2
Journal of Neuroscience Methods·2021· 1 citedOpen Access
Gene Therapy for Duchenne Muscular Dystrophy
Journal of Neuromuscular Diseases·2021· 185 citedOpen Access
Exon Skipping as a Therapeutic for Neurofibromatosis Type I
2021Open Access
Knockdown of Muscle-Specific Ribosomal Protein L3-Like Enhances Muscle Function in Healthy and Dystrophic Mice
Nucleic Acid Therapeutics·2021· 13 cited
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
Human Molecular Genetics·2021· 27 citedOpen Access
RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways
Nature Communications·2021· 43 citedOpen Access
Dose-Dependent Microdystrophin Expression Enhancement in Cardiac Muscle by a Cardiac-Specific Regulatory Element
Human Gene Therapy·2021· 10 cited
BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
Molecular Therapy — Nucleic Acids·2021· 17 citedOpen Access
Systemic antisense therapeutics inhibiting <i>DUX4</i> expression improves muscle function in an FSHD mouse model
2021· 1 citedOpen Access
Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD
UNC Libraries·2020Open Access
Mutation-Directed Therapeutics for Neurofibromatosis Type I
Molecular Therapy — Nucleic Acids·2020· 32 citedOpen Access
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Neurology·2020· 310 citedOpen Access
Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease
Frontiers in Physiology·2020· 11 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Linda Popplewell(9), Frank S. Walsh(9), Takis Athanasopoulos(9), Jennifer E. Morgan(6), Francesco Muntoni(6), Ian R. Graham(6), Chris Barton(6), Taeyoung Koo(6), Capucine Trollet(6), Dominic J. Wells(5), Donald R. Love(5), Hilary J. Gower(5), Alberto Malerba(5), Virginia Arechavala‐Gomeza(4), Michela Guglieri(4), Steve D. Wilton(4), Volker Straub(4), Kay E. Davies(4), Glenn E. Morris(4), Stephen E. Moore(4)